Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | SGMS2 | Q8NHU3 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3927143 | 0.91 | LRRK2 (0.44) | DGAT1SGMS2MEN1KMT2ALRRK2 | |
| SCHEMBL3936790 | 0.80 | AKT1 (0.37) | DGAT1KMT2AAKT1RAB9A | |
| SCHEMBL3929285 | 0.78 | MEN1 (0.52) | SGMS2MEN1KMT2AAKT1MAPK1 | |
| SCHEMBL13536239 | 0.77 | DGAT1 (0.60) | DGAT1MEN1KMT2AMAPK1 | |
| SCHEMBL31240669 | 0.77 | DGAT1 (0.60) | DGAT1MEN1KMT2AMAPK1 | |
| SCHEMBL10221396 | 0.77 | DGAT1 (0.52) | DGAT1MEN1KMT2ARAB9A | |
| SCHEMBL15639715 | 0.75 | DGAT1 (0.49) | DGAT1MAPK1GPR132 | |
| SCHEMBL15554329 | 0.75 | DGAT1 (0.54) | DGAT1MEN1KMT2A | |
| SCHEMBL16337257 | 0.75 | DGAT1 (0.54) | DGAT1MEN1KMT2ARAB9A | |
| SCHEMBL30345297 | 0.75 | DGAT1 (0.54) | DGAT1MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7504401-B2 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | DGAT1 4110/4885SGMS2 4294/4885MEN1 2463/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | DGAT1 4003/4885SGMS2 4258/4885MEN1 2359/4885 |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | DGAT1 3611/4885SGMS2 4310/4885MEN1 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.